BMRN NASDAQ
BioMarin Pharmaceutical Inc.
1W: -1.9%
1M: -6.9%
3M: -9.8%
YTD: -6.9%
1Y: +1.6%
3Y: -32.6%
5Y: -25.3%
$55.35
-0.40 (-0.72%)
Weekly Expected Move ±3.9%
$52
$54
$56
$58
$60
Credit Risk of going bust: lower than 58% of companies Debt: 28.2% of company value Bonds: $170.1M held by 149 funds, 129 bp over Treasuries → details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $1.66 (down 97%), BioMarin Pharmaceutical Inc. would be worth roughly what it owes.
Total debt $4.20B against a stock market value of $10.71B.
Distance to default 5.92 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $2.42B (short-term plus half of long-term), stock volatility 34.6%; Altman Z'' 2.74. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $1.66 (down 97%), BioMarin Pharmaceutical Inc. would be worth roughly what it owes.
Total debt $4.20B against a stock market value of $10.71B.
Distance to default 5.92 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $2.42B (short-term plus half of long-term), stock volatility 34.6%; Altman Z'' 2.74. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
6 relationships5
As Filer
counterparties named
1
As Counterparty
mentioned by others
2
Rel. Types
2023-12-20
Earliest Filing
2026-02-12
Latest Filing
partner: 3
target: 2
Counterparties (Filed by BMRN)
5 relationshipsCompanies named in BMRN's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Amicus Therapeutics, Inc. | FOLD | target | Target of the pending acquisition funded by the Notes and Term Loan facilities. | 2026-02-12 | View |
| Amicus Therapeutics, Inc. | AMCX | target | Target company in the proposed merger agreement with BioMarin Pharmaceutical Inc. | 2025-12-19 | View |
| Elliott Investment Management L.P. | — | partner | Entered into a Cooperation Agreement regarding Board composition and strategic review. | 2023-12-20 | View |
| Elliott Associates, L.P. | — | partner | Entered into a Cooperation Agreement regarding Board composition and strategic review. | 2023-12-20 | View |
| Elliott International, L.P. | — | partner | Entered into a Cooperation Agreement regarding Board composition and strategic review. | 2023-12-20 | View |
Mentioned As Counterparty
1 mentionsOther companies that named BMRN in their SEC 8-K filings.
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-06 | Earnings Release | View | |
| 2026-09-30 | Material Agreement | Agreement | View |
| 2026-09-15 | Other Events | View | |
| 2026-09-14 | Officer/Director Change | View | |
| 2026-09-01 | Other Events | View | |
| 2026-08-31 | Material Agreement; Regulation FD; Exhibits | Agreement | View |
| 2026-08-18 | Material Agreement; Regulation FD; Exhibits | Agreement | View |
| 2026-08-06 | Earnings Release; Exhibits | View | |
| 2026-07-13 | Other Events; Exhibits | View | |
| 2026-06-04 | Officer/Director Change; Shareholder Vote | View | |
| 2026-05-04 | Earnings Release; Exhibits | View | |
| 2026-04-27 | Material Agreement; Acquisition/Disposition; Financial Obligation; Regulation FD; Exhibits | Agreement Acquisition | View |
| 2026-04-23 | Other Events | View | |
| 2026-03-16 | Other Events | View | |
| 2026-02-23 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-02-12 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Regulation FD Dis | Agreement | View |
| 2026-01-29 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2026-01-26 | Results of Operations and Financial Condition; Regulation FD Disclosure; Other Events; Financial Sta | View | |
| 2026-01-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-12-22 | Other Events | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR